• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein.人血浆前激肽释放酶(激肽释放酶原)-激肽释放酶酶系统的研究。II. 关于高岭土激活的精氨酸酯酶与血浆激肽释放酶关系的证据。
J Clin Invest. 1969 Jan;48(1):23-32. doi: 10.1172/JCI105971.
2
Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.人血浆α2-巨球蛋白。一种血浆激肽释放酶抑制剂。
J Exp Med. 1970 Aug 1;132(2):329-52. doi: 10.1084/jem.132.2.329.
3
Observations on the plasma kallikreinogen (prekallikrein)-kallikrein enzyme system.关于血浆激肽释放酶原(前激肽释放酶)-激肽释放酶酶系统的观察
Trans Assoc Am Physicians. 1968;81:40-8.
4
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins.人血浆前激肽释放酶(激肽原)-激肽释放酶酶系统的研究。I. 血浆激肽释放酶的分离与纯化。
J Clin Invest. 1969 Jan;48(1):11-22. doi: 10.1172/JCI105959.
5
Contact activation of human plasma prorenin in vitro.人血浆中血管紧张素原在体外的接触激活
J Lab Clin Med. 1981 Jun;97(6):771-8.
6
Prekallikrein activator and kallikrein in acetone- and kaolin-activated rat plasma.丙酮和高岭土激活的大鼠血浆中的前激肽释放酶激活剂和激肽释放酶
Acta Pharmacol Toxicol (Copenh). 1979 Sep;45(3):174-80. doi: 10.1111/j.1600-0773.1979.tb02379.x.
7
Immunochemical studies of plasma kallikrein.血浆激肽释放酶的免疫化学研究。
J Clin Invest. 1974 Dec;54(6):1444-54. doi: 10.1172/JCI107892.
8
The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states.人血浆中的激肽原-激肽酶系统。成分测定及疾病状态观察。
Ann Intern Med. 1969 Oct;71(4):763-73. doi: 10.7326/0003-4819-71-4-763.
9
Plasma arginine esterase in cystic fibrosis: kinetics of activation, identification as plasma kallikrein, reaction with alpha 2-macroglobulin and comparison with levels in normal plasma.囊性纤维化中的血浆精氨酸酯酶:激活动力学、鉴定为血浆激肽释放酶、与α2-巨球蛋白的反应以及与正常血浆水平的比较。
Pediatr Res. 1982 Aug;16(8):613-20. doi: 10.1203/00006450-198208000-00006.
10
Arginine esterase in cerebrospinal fluid and pro-arginine esterase in plasma from patients with migraine.偏头痛患者脑脊液中的精氨酸酯酶及血浆中的前精氨酸酯酶
Acta Neurol Scand. 1976 Oct;54(4):301-11. doi: 10.1111/j.1600-0404.1976.tb04361.x.

引用本文的文献

1
The Procoagulant Activity of Apoptotic Cells Is Mediated by Interaction with Factor XII.凋亡细胞的促凝血活性是通过与凝血因子 XII 相互作用介导的。
Front Immunol. 2017 Sep 25;8:1188. doi: 10.3389/fimmu.2017.01188. eCollection 2017.
2
Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma.血浆中前激肽释放酶-高分子量激肽原复合物的功能与免疫化学
J Clin Invest. 1980 Feb;65(2):413-21. doi: 10.1172/JCI109684.
3
Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.血浆α2-巨球蛋白(激肽释放酶抑制剂)对血浆凝血活酶前体与激肽释放酶的分离作用
J Clin Invest. 1971 Oct;50(10):2084-90. doi: 10.1172/JCI106702.
4
Studies on the prekallikrein-bradykininogen system in liver disease.肝脏疾病中前激肽释放酶-缓激肽原系统的研究。
J Clin Pathol. 1972 May;25(5):410-4. doi: 10.1136/jcp.25.5.410.
5
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins.人血浆前激肽释放酶(激肽原)-激肽释放酶酶系统的研究。I. 血浆激肽释放酶的分离与纯化。
J Clin Invest. 1969 Jan;48(1):11-22. doi: 10.1172/JCI105959.
6
The profile of vascular permeability factors in dilute guinea-pig plasma.豚鼠稀释血浆中血管通透性因子的概况
Br J Exp Pathol. 1972 Dec;53(6):597-607.
7
Immunochemical studies of plasma kallikrein.血浆激肽释放酶的免疫化学研究。
J Clin Invest. 1974 Dec;54(6):1444-54. doi: 10.1172/JCI107892.
8
The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor).人和兔血浆中激肽形成系统的首个成分。它与凝血因子XII(哈格曼因子)的关系。
J Exp Med. 1971 Oct 1;134(4):986-1004. doi: 10.1084/jem.134.4.986.
9
Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.人血浆α2-巨球蛋白。一种血浆激肽释放酶抑制剂。
J Exp Med. 1970 Aug 1;132(2):329-52. doi: 10.1084/jem.132.2.329.
10
Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.慢性肝病中的Hageman因子、高分子量激肽原和前激肽释放酶
J Clin Pathol. 1986 Sep;39(9):1003-5. doi: 10.1136/jcp.39.9.1003.

本文引用的文献

1
Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein.遗传性血管性水肿。II. 血清球蛋白通透性因子和/或血浆激肽释放酶抑制剂缺乏。
J Allergy. 1962 Jul-Aug;33:330-41. doi: 10.1016/0021-8707(62)90032-1.
2
The mode of action of Hageman factor in the release of plasma kinin.哈格曼因子在血浆激肽释放中的作用方式。
J Physiol. 1960 May;151(2):238-52. doi: 10.1113/jphysiol.1960.sp006434.
3
The activation of human plasminogen by streptokinase.链激酶对人纤溶酶原的激活作用。
J Biol Chem. 1955 Apr;213(2):881-91.
4
USE OF HEPARIN IN DISTINGUISHING PLASMA KALLIKREIN FROM PF/DIL.肝素在区分血浆激肽释放酶与PF/DIL中的应用。
Proc Soc Exp Biol Med. 1965 Jul;119:652-6. doi: 10.3181/00379727-119-30262.
5
SOME BIOCHEMICAL AND PHYSICAL PROPERTIES OF THE HUMAN PERMEABILITY GLOBULINS.人通透性球蛋白的一些生化和物理特性
Br J Exp Pathol. 1964 Dec;45(6):604-11.
6
ASSAY OF UROKINASE PREPARATIONS WITH THE SYNTHETIC SUBSTRATE ACETYL-L-LYSINE METHYL ESTER.用合成底物乙酰 - L - 赖氨酸甲酯测定尿激酶制剂
J Lab Clin Med. 1964 Jul;64:145-53.
7
THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR.活化的哈格曼因子诱导人血浆中通透性增加活性
Br J Exp Pathol. 1964 Jun;45(3):328-45.
8
EFFECT OF HEXADIMETHRINE BROMIDE ON PLASMA KININ FORMATION, HYDROLYSIS OF P-TOSYL-L-ARGININE METHYL ESTER AND FIBRINOLYSIS.溴化己二甲铵对血浆激肽形成、对甲苯磺酰-L-精氨酸甲酯水解及纤维蛋白溶解的影响
Br J Pharmacol Chemother. 1964 Feb;22(1):87-103. doi: 10.1111/j.1476-5381.1964.tb01546.x.
9
THE PRESENCE OF TWO PERMEABILITY GLOBULINS IN HUMAN SERUM.人血清中两种通透性球蛋白的存在。
J Clin Invest. 1963 Aug;42(8):1353-61. doi: 10.1172/JCI104819.
10
Relationship between air temperature and mean radiant temperature in thermal comfort.热舒适中气温与平均辐射温度的关系。
Nature. 1962 Nov 10;196:587. doi: 10.1038/196587a0.

人血浆前激肽释放酶(激肽释放酶原)-激肽释放酶酶系统的研究。II. 关于高岭土激活的精氨酸酯酶与血浆激肽释放酶关系的证据。

Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein.

作者信息

Colman R W, Mattler L, Sherry S

出版信息

J Clin Invest. 1969 Jan;48(1):23-32. doi: 10.1172/JCI105971.

DOI:10.1172/JCI105971
PMID:4237065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC322188/
Abstract

Evidence is presented in this paper that the kaolin-activated arginine esterase of plasma is related to plasma kallikrein activity. Such a relationship is based on studies that (1) establish a constant ratio of esterase activity on various synthetic substrates for the kaolin-activated arginine esterase, purified kallikrein(s), and preparations obtained during the fractionation procedure; (2) exclude other known plasma and tissue arginine esterases; (3) confirm the requirement for factor XII in the activation of the enzyme precursor; and (4) show similarities in behavior between the plasma esterase and purified kallikrein(s) toward a variety of inhibitors. Based on this probable identification, evidence is provided that the concentration of active factor XII determines the rate of activation of plasma kallikreinogen, and that the activation may be blocked by polybrene. Once activated, plasma kallikrein is rapidly inactivated by the naturally occurring plasma inhibitor, but the inhibition is incomplete. Acid or chloroform treatment of plasma rapidly inactivates the plasma inhibitor without affecting the concentration of plasma kallikreinogen. Another plasma arginine esterase with properties suggestive of permeability factor is activated by factor XII in the presence of synthetic substrates, but only at low ionic strength. The data suggest that this enzyme is closely related to plasma kallikrein and that it arises from a common precursor.

摘要

本文提供的证据表明,血浆中高岭土激活的精氨酸酯酶与血浆激肽释放酶活性相关。这种关系基于以下研究:(1)确定了高岭土激活的精氨酸酯酶、纯化的激肽释放酶以及分级分离过程中获得的制剂对各种合成底物的酯酶活性的恒定比例;(2)排除了其他已知的血浆和组织精氨酸酯酶;(3)证实了因子 XII 在酶原激活中的必要性;(4)显示了血浆酯酶和纯化的激肽释放酶对多种抑制剂的行为相似性。基于这种可能的鉴定,提供的证据表明,活性因子 XII 的浓度决定了血浆激肽释放酶原的激活速率,并且该激活可能被聚凝胺阻断。一旦被激活,血浆激肽释放酶会迅速被天然存在的血浆抑制剂灭活,但这种抑制并不完全。用酸或氯仿处理血浆会迅速使血浆抑制剂失活,而不影响血浆激肽释放酶原的浓度。另一种具有提示渗透因子性质的血浆精氨酸酯酶在合成底物存在下被因子 XII 激活,但仅在低离子强度下。数据表明,这种酶与血浆激肽释放酶密切相关,并且它来自共同的前体。